Immatics presenting at Hanson Wade Gamma Delta T Therapy Summit
Sep 30, 2020
Join us and others to explore Antibody & Cell Based Gamma Delta T Approaches at the Gamma Delta T Therapy Summit (virtual event, September 30).
Wednesday, September 30, 4.30pm BST (11.30am EDT/ 5.30pm CEST)
Presentation: ACTallo®, an Off-the-Shelf Adoptive Cell Therapy Approach Using αβ TCR-transduced γδ T Cells
- Immatics believes that γδ T cells are ideally suited for allogenic Adoptive Cell Therapy approaches because they naturally infiltrate tumors, possess intrinsic antitumor activity and recognize target cells in an HLA/ peptide independent fashion, not causing Graft-versus-Host Disease.
- ACTallo® is a process developed by Immatics for the manufacture of allogeneic, off-the-shelf, TCR-engineered cellular therapies derived from healthy donors’ γδ T cells.
- At the laboratory scale, Immatics has observed that its proprietary manufacturing process could generate hundreds of doses from a single donor.
- Immatics is currently translating these lessons into large scale solutions.
Presenter: Steffen Walter, CTO Immatics
Wednesday, September 30, 5.30pm BST (12.30pm EDT/ 6.30pm CEST)
Panel Discussion: Live Q&A with Speakers
Richard Lopez, CEO PhosphoGam
Steffen Walter, CTO Immatics
Lawrence Lamb, CSO In8Bio
Stewart Abbot, CSO Adicet Bio
Oliver Nussbaumer, VP Immunology GammaDelta Therapeutics
We are looking forward to e-meeting you!
Learn more about the Hanson Wade Gamma Delta T Therapy Summit here.